Your browser is no longer supported. Please, upgrade your browser.
KRON Kronos Bio, Inc. daily Stock Chart
Kronos Bio, Inc.
Index- P/E- EPS (ttm)-1.90 Insider Own5.50% Shs Outstand52.60M Perf Week1.12%
Market Cap1.71B Forward P/E- EPS next Y- Insider Trans69.40% Shs Float5.25M Perf Month-
Income-25.10M PEG- EPS next Q- Inst Own- Short Float- Perf Quarter-
Sales- P/S- EPS this Y-139.80% Inst Trans- Short Ratio- Perf Half Y-
Book/sh- P/B- EPS next Y- ROA- Target Price- Perf Year-
Cash/sh1.55 P/C20.92 EPS next 5Y- ROE- 52W Range25.50 - 34.90 Perf YTD19.76%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-7.11% Beta-
Dividend %- Quick Ratio13.30 Sales past 5Y- Gross Margin- 52W Low27.13% ATR3.01
Employees45 Current Ratio13.30 Sales Q/Q- Oper. Margin- RSI (14)- Volatility6.75% -
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.14 Prev Close33.17
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume917.73K Price32.42
Recom- SMA203.94% SMA503.94% SMA2003.94% Volume132,223 Change-2.26%
Oct-22-20 08:00AM  
Oct-14-20 04:05PM  
Oct-09-20 03:49PM  
Oct-08-20 08:00PM  
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib, a selective inhibitor targeting spleen tyrosine kinase in acute myeloid leukemia patients. The company is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors. Kronos Bio, Inc. is founded in 2017 and is headquartered in San Mateo, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Omega Fund V, L.P.10% OwnerOct 14Buy19.00450,0008,550,0003,818,283Oct 16 03:58 PM
Stampacchia OtelloDirectorOct 14Buy19.00450,0008,550,0003,818,283Oct 16 03:56 PM
Ridloff ElenaDirectorOct 14Buy19.002,63049,9702,630Oct 16 03:52 PM
MARTIN JOHN CDirectorOct 14Buy19.0075,8001,440,2001,952,364Oct 16 03:51 PM
Kosacz BarbaraCOO & General CounselOct 14Buy19.005,25099,750614,600Oct 16 03:40 PM
Dinsmore ChristopherChief Scientific OfficerOct 14Buy19.005,25099,7505,250Oct 16 03:39 PM
Al-Wakeel Yasir B.Chief Financial OfficerOct 14Buy19.005,25099,75037,219Oct 16 03:38 PM
Bischofberger Norbert W. & Ing10% OwnerOct 14Buy19.0095,5001,814,5004,370,496Oct 16 03:36 PM
BISCHOFBERGER NORBERT WPresident & CEOOct 14Buy19.0095,5001,814,5004,370,496Oct 16 03:29 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 All Rights Reserved.